BofA analyst Ruplu Bhattacharya raised the firm's price target on Enovix to $8 from $7 and keeps a Neutral rating on the shares after the company reported a fiscal Q1 beat. The firm is applying a higher multiple as it sees a second smartphone customer also agreeing to an alternate testing methodology as "an incremental positive for ultimate revenue generation from smartphones," the analyst tells investors.
